Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01546532 · ClinicalTrials.gov registry record · Phase 2
Renal Hemodynamic Effects of RLX030A in Subjects With Chronic Heart Failure (CHF)
A Phase 2 study, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 118
- Enrollment target
NCT01546532 is a Phase 2 study that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 118 participants.
The verdict
NCT01546532, a Phase 2 study, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 118 participants
- Enrollment target
Study Summary
This study will assess the renal hemodynamic effect of RLX030 infusion in subjects with chronic heart failure. In addition safety and effects on renal function and biomarkers will be assessed.
Interventions
- DRUG Placebo
- DRUG RLX030
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 118 participants |
| Start Date | 2012-02 |
| Est. Completion | 2012-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01546532
The ClinicalTrials.gov registry entry for NCT01546532 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 118 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01546532 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01546532 about?
NCT01546532 is a clinical study titled "Renal Hemodynamic Effects of RLX030A in Subjects With Chronic Heart Failure (CHF)". This study will assess the renal hemodynamic effect of RLX030 infusion in subjects with chronic heart failure. In addition safety and effects on renal function and biomarkers will be assessed.
What is the current status of trial NCT01546532?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 118 participants. The study started on 2012-02. Estimated completion is 2012-12.
What interventions are being tested in trial NCT01546532?
The interventions under investigation include: Placebo (DRUG), RLX030 (DRUG).
Who is sponsoring clinical trial NCT01546532?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.